Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Dr Joslyn Ngu, 23 Nov 2017
Highlights from the Joint Cancer Genetics Meeting and the 15th International Meeting on the Psychosocial Aspects of Hereditary Cancer (IMPAHC) 2017

Genetic testing vital for lung cancer diagnosis, management

Dr Joslyn Ngu
04 Dec 2017

Genetic testing has changed the landscape of lung cancer and every patient needs to undergo testing, says a specialist.

Testing allows for the determination of actionable genetic alterations in lung cancer and is vital as it allows better treatment, said clinical oncologist Dr Tho Lye Mun. Research has found that patients with an oncogenic driver mutation who were given targeted therapy had better survival rate than those who did not receive targeted therapy and patients without an oncogenic driver. [JAMA 2014;311(19):1998–2006]

With the advancement in genetic testing, diagnosing lung cancer now involves an additional step. Besides conventional diagnosis using morphological or basic immunohistochemical features, for example to differentiate small cell lung cancer versus non-small cell lung carcinoma (NSCLC), identifying actionable genetic alterations such as EGFR, ALK , ROS-1 and PDL-1 should also be part of routine lung cancer diagnosis, said Tho.

The ability to classify patients in a more precise manner allows for more appropriate therapeutic strategy and for patients to receive the maximum effect of molecularly targeted drugs or immunotherapy. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Dr Joslyn Ngu, 23 Nov 2017
Highlights from the Joint Cancer Genetics Meeting and the 15th International Meeting on the Psychosocial Aspects of Hereditary Cancer (IMPAHC) 2017